



Financial Tear Sheet

Corporate Profile

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today. The T2Sepsis Solution™ is a unique approach that combines the standard of care for the management of sepsis patients with T2 Biosystems' products, including the T2Dx® Instrument and T2Candida® Panel, and the T2Bacteria® Panel, which is commercially available in Europe and other countries that accept the CE Mark and available for research use only in the U.S. Powered by the proprietary T2 Magnetic Resonance technology, or T2MR®, the T2Sepsis Solution is proven to deliver better patient care and greater cost savings. Hospital customer experience has demonstrated faster time to effective treatment, shortened ICU and hospital lengths of stay, reduced use of unnecessary antifungals, and millions of dollars in savings. T2 Biosystems has an active pipeline of future sepsis products including additional species and antibiotic resistance, as well as tests for Lyme disease and hemostasis. For more information, please visit www.t2biosystems.com.

Primary IR Contact

Investor

Contact Information

E-mail:

ir@T2Biosystems.com

Stock Performance

TTOO (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$5.23
Change (%)	▲ 0.11 (2.15%)
Volume	168,828
52 Week Low	\$2.50
Market Cap	\$187,364,541
Rolling EPS	-1.91
PE Ratio	0

Shares Outstanding 35,824,960

Data as of 01/19/18 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Headlines & Events

01/04/18 - 4:05 p.m.
 T2 Biosystems Announces Preliminary Fourth Quarter 2017
 Financial Results and Provides Update on T2Bacteria Panel

There are currently no events scheduled.

11/27/17 - 8:01 a.m.
 T2 Biosystems to Attend the Global Mizuho Investor
 Conference

11/20/17 - 9:27 a.m.
 T2 Biosystems Announces New T2Bacteria RUO Panel
 Data Presented at AMP 2017

SEC Filings

Filing Date	Form
01/08/18	8-K
01/03/18	4
01/03/18	4
01/03/18	4

Corporate Governance

John McDonough	Chief Executive Officer
Darlene Deptula-Hicks	Senior Vice President and Chief Financial Officer
Joanne Spadoro, Ph.D.	Chief Operations Officer
Tom Lowery, Ph.D.	Chief Scientific Officer
Rahul Dhanda	Senior Vice President, Corporate Development & Marketing
Michael Gibbs, Esq.	Vice President and General Counsel
Alec Barclay	VP, Product Development & Program Management